Breast

Clinical Treatment Impact of a LOW/LOW Breast Cancer Index (BCI) Result Dr Naughton

412 0 Acute Lymphoblastic Leukemia

Dr Naughton communicates the clinical actionability of a Low Risk/Low Likelihood of Benefit BCI result in his practice.

Play Add to

Breast Cancer Index (BCI) is an objective measure to help women struggling with decisions Dr Naughton

84 0 Acute Lymphoblastic Leukemia

Endocrine therapy may cause many bothersome side effects, often affecting a patients compliance. Dr Naughton suggests BCI as a tool to objectively help patients understand their likelihood of benefit and help encourage them to continue therapy, if appropriate.

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

Breast Cancer Index (BCI) Validation Includes Both TAM and AI Treated Patients and letrozole

82 0 Acute Lymphoblastic Leukemia

Breast Cancer Index (BCI) validation studies included both women treated with aromatase inhibitors (AI) and women treated with tamoxifen (Tam). The three validation studies included patients treated with Tam only (Stockholm), either anastrozole or Tam (ATAC), and Tam with a transition to letrozole (MA.17).

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

An Advance in Molecular Medicine to Manage Breast Cancer extended endocrine therapy

127 0 Acute Lymphoblastic Leukemia

In the era of molecular medicine, there is now a tool called Breast Cancer Index (BCI) to help physicians determine whether to recommend extended endocrine therapy.

Play Add to

High Risk Does Not Translate to High Benefit From Extended Endocrine Therapy

139 0 Acute Lymphoblastic Leukemia

Dr. Naughton recognizes the difference between risk of recurrence and likelihood of benefit from extended endocrine therapy, noting the two do not always correlate, as they can be based on separate biological mechanisms. A patient at high risk of recurrence does not inherently imply that patient will respond to a particular therapy.

Play Add to

Personalizing Cancer Care Beyond 5 Years

141 0 Acute Lymphoblastic Leukemia

Previously, risk reduction from treatment with endocrine therapy has been represented as a general percentage for all patients treated. Knowing that in reality each patient responds differently, Dr. Naughton stresses the importance of tailoring treatment decisions based on the individual patient situation.

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

Endocrine Therapy for Early Stage Breast Cancer is Not Benign

274 0 Acute Lymphoblastic Leukemia

Dr. Naughton discusses the bothersome side effects and serious safety risks associated with endocrine therapy. He emphasizes the need to weigh patient benefit versus the impact on quality of life due to these side effects and safety risks when considering patient treatment options.

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

What Breast Cancer Index (BCI) Does For Me

207 0 Acute Lymphoblastic Leukemia

Dr Naughton discusses challenges facing women who are evaluating extention of adjuvant endocrine treatment and how he finds Breast Cancer Index helpful.

Play Add to

Breast Cancer Index (BCI) Payer Education Dr Stephen C. Malamud

189 0 Acute Lymphoblastic Leukemia

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure patient access and cost reimbursement.

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

Breast Cancer Index (BCI) and Adherence Dr Stephen C. Malamud

318 0 Acute Lymphoblastic Leukemia

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as the Breast Cancer Index (BCI) and its impact on patient confidence in their treatment plan.

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

Breast Cancer Index (BCI) Affects and Survivorship Dr Susan K. Boolbol

205 0 Acute Lymphoblastic Leukemia

Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer Index (BCI) in treatment decision making.

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

Benefits of Breast Cancer Index Dr Stephen C. Malamud

202 0 Acute Lymphoblastic Leukemia

Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer Index (BCI) as a test that separates those patients who are more likely to benefit from those who are unlikely to benefit from extended endocrine therapy.

For more information, visit: http://www.breastcancerindex.com http://www.answersbeyond5.com http://www.twitter.com/answersbyond5 http://www.facebook.com/answersbeyond5

Play Add to

Breast

Benefits of Breast Cancer Index Dr Stephen C. Malamud

Date added (newest)

Clinical Treatment Impact of a LOW/LOW Breast Cancer Index (BCI) Result Dr Naughton

Breast Cancer Index (BCI) is an objective measure to help women struggling with decisions Dr Naughton

Breast Cancer Index (BCI) Validation Includes Both TAM and AI Treated Patients and letrozole

An Advance in Molecular Medicine to Manage Breast Cancer extended endocrine therapy

High Risk Does Not Translate to High Benefit From Extended Endocrine Therapy

Personalizing Cancer Care Beyond 5 Years

Endocrine Therapy for Early Stage Breast Cancer is Not Benign

What Breast Cancer Index (BCI) Does For Me

Breast Cancer Index (BCI) Payer Education Dr Stephen C. Malamud

Breast Cancer Index (BCI) and Adherence Dr Stephen C. Malamud

Breast Cancer Index (BCI) Affects and Survivorship Dr Susan K. Boolbol

Benefits of Breast Cancer Index Dr Stephen C. Malamud

Clinical Treatment Impact of a LOW/LOW Breast Cancer Index (BCI) Result Dr Naughton

Dr Naughton communicates the clinical actionability of a Low Risk/Low Likelihood of Benefit BCI result in his practice.

Breast Cancer Index (BCI) is an objective measure to help women struggling with decisions Dr Naughton

Breast Cancer Index (BCI) Validation Includes Both TAM and AI Treated Patients and letrozole

An Advance in Molecular Medicine to Manage Breast Cancer extended endocrine therapy

In the era of molecular medicine, there is now a tool called Breast Cancer Index (BCI) to help physicians determine whether to recommend extended endocrine therapy.

High Risk Does Not Translate to High Benefit From Extended Endocrine Therapy

Personalizing Cancer Care Beyond 5 Years

Endocrine Therapy for Early Stage Breast Cancer is Not Benign

What Breast Cancer Index (BCI) Does For Me

Dr Naughton discusses challenges facing women who are evaluating extention of adjuvant endocrine treatment and how he finds Breast Cancer Index helpful.

Breast Cancer Index (BCI) Payer Education Dr Stephen C. Malamud

Breast Cancer Index (BCI) and Adherence Dr Stephen C. Malamud

Breast Cancer Index (BCI) Affects and Survivorship Dr Susan K. Boolbol

Benefits of Breast Cancer Index Dr Stephen C. Malamud

Clinical Treatment Impact of a LOW/LOW Breast Cancer Inde...